Gingipain inhibitors as an innovative therapy for periodontal and associated-systemic diseases: a systematic review
Open Access
- 21 August 2025
- journal article
- review article
- Published by Springer Nature in Clinical Oral Investigations
- Vol. 29 (9) , 1-12
Abstract
Periodontal diseases (PDs) are prevalent chronic inflammatory conditions linked to the progression of systemic disorders. Gingipains, cysteine proteases produced by Porphyromonas gingivalis, are key virulence factors involved in PD pathogenesis and host-tissue degradation. Inhibiting these enzymes has emerged as a promising therapeutic approach. Objective: This systematic review evaluates the potential of gingipain inhibitors in the management of PDs and related systemic conditions. Methods: A systematic search was conducted across PubMed, Scopus, and Web of Science using the PICOS framework. Studies were evaluated based on their objectives, experimental models, inhibitor types, and outcomes. Results: Seven preclinical studies met the inclusion criteria. No clinical studies were identified. In preclinical models, gingipain inhibitors demonstrated consistent therapeutic benefits, including reduced inflammation, bacterial load, and tissue destruction in PDs, as well as improved outcomes in cardiovascular and AD models. Dual inhibitors targeting both Rgp and Kgp enzymes were more effective than single-target agents. Conclusion: Gingipain inhibitors hold promise as therapeutic agents for PDs and associated systemic diseases. However, the absence of clinical studies highlights the need for further development and clinical evaluation to support their translational potential. Clinical relevance: By targeting specific and key components of host–bacterium interactions, gingipain inhibitors represent a promising adjunctive therapy for modulating periopathogen virulence factors, thereby mitigating the progression of PDs and associated systemic diseases.Keywords
Funding Information
- Universidade do Porto
This publication has 62 references indexed in Scilit:
- Periodontal disease as a model to study chronic inflammation in agingGeroScience, 2023
- Computational Study of the Inhibition of RgpB Gingipain, a Promising Target for the Treatment of Alzheimer’s DiseaseJournal of Chemical Information and Modeling, 2023
- The Link Between Periodontitis and Alzheimer’s Disease: Reality or Yet Another AssociationCurrent Oral Health Reports, 2022
- The sialidase inhibitor, DANA, reduces Porphyromonas gingivalis pathogenicity and exerts anti‐inflammatory effects: An in vitro and in vivo experimentJournal of Periodontology, 2020
- Treatment of Porphyromonas gulae infection and downstream pathology in the aged dog by lysine‐gingipain inhibitor COR388Pharmacology Research & Perspectives, 2020
- Administration of systemic antibiotics during non-surgical periodontal therapy—a consensus reportClinical Oral Investigations, 2018
- Periodontitis in US AdultsThe Journal of the American Dental Association, 2018
- Inhibition of gingipains prevents Porphyromonas gingivalis-induced preterm birth and fetal death in pregnant miceEuropean Journal of Pharmacology, 2018
- Cathepsin B plays a critical role in inducing Alzheimer’s disease-like phenotypes following chronic systemic exposure to lipopolysaccharide from Porphyromonas gingivalis in miceBrain, Behavior, and Immunity, 2017
- Chlorhexidine mouthwash as an adjunct to mechanical therapy in chronic periodontitisThe Journal of the American Dental Association, 2017